Browsing Over 63 Sessions

Sort By

Medscape Oncology Global - Targets of Antibody-Drug Conjugates in NSCLC: Diagnostics, Emerging Therapies, and Future Prospects (ID 140)

Time
18:30 - 20:00

BeiGene Switzerland GmbH - Standard of Care is Not Enough! Talking Immunotherapy Clinical Trials in GI Cancers (ID 106)

Time
18:30 - 19:40

Seagen - Expert Opinion: Considerations for Managing HER2+ Breast Cancer and Brain Metastases (ID 130)

Time
13:00 - 14:15

Merck - From complex to simple: The journey to strategic sequencing in the management of mCRC (ID 96)

Time
18:00 - 19:30

Astellas - From landmark data to clinical excellence: Improving outcomes in LA/mUC (ID 121)

Time
18:30 - 20:00

Novartis - Guiding Through Oesophageal Cancer: Expert Insights on the Patient Journey From Diagnosis to Treatment (ID 87)

Time
10:15 - 11:45

Pfizer Oncology - Is it time to raise the bar for ALK+ NSCLC patients? (ID 111)

Time
18:30 - 20:00
7.3.S - Strasbourg Auditorium EONS Industry Satellite Symposium

AstraZeneca, Eli Lilly, Novartis - Experience of living with Early Breast Cancer, treatment and beyond: What are we missing

Date
Sat, 10.09.2022
Time
12:00 - 13:30
Room
7.3.S - Strasbourg Auditorium

Sanofi and Regeneron - Decision-Making Discussions: IO in aNSCLC (ID 136)

Time
13:00 - 14:30

Janssen-Cilag International NV - Precision approaches in EGFR-mutant NSCLC: Optimising outcomes for patients (ID 102)

Time
13:00 - 14:30

MSD - Triple Negative Breast Cancer: An Evolving Treatment Landscape (ID 126)

Time
18:30 - 20:00

Servier - Interpreting real-world data to better manage patients with metastatic colorectal cancer (ID 92)

Time
18:00 - 19:30